Results 181 to 190 of about 8,451 (198)

Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma

World Allergy Organization Journal, 2022
Karl-Christian Bergmann, Torsten Zuberbier, Jean Bousquet   +2 more
exaly  

Mepolizumab use in cystic fibrosis‐associated allergic bronchopulmonary aspergillosis

Respirology Case Reports, 2021
Maeve Boyle
exaly  

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Clinical Therapeutics, 2019
Robert Price, Guy Brusselle, Frank Albers   +2 more
exaly  

The safety of mepolizumab for the treatment of asthma

Expert Opinion on Drug Safety, 2017
J M Fitzgerald, Jm Fitzgerald
exaly  

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

Pediatric Pulmonology, 2019
Robert Price, Atul Gupta, Jonathan Steinfeld   +2 more
exaly  

Mepolizumab—a novel option for the treatment of hypereosinophilic syndrome in childhood

Pediatric Allergy and Immunology, 2018
Carsten Schwarz, Carsten Schwarz
exaly  

Mepolizumab

Reactions Weekly, 2010
openaire   +1 more source

Mepolizumab in eosinophilic disorders

Expert Review of Clinical Immunology, 2011
Philip E Putnam, J Pablo Abonia
exaly  

<p>Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease</p>

International Journal of COPD, 2019
Takudzwa Mkorombindo, Mark Dransfield
exaly  

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma

Journal of Allergy and Clinical Immunology, 2017
Pranabashis Haldar, Hector Ortega, Ian Pavord   +2 more
exaly